Clinical trials: Single Women
Cervical Cancer
A Clinical Study to Evaluate Efficacy and Safety of HLX10 Combined With Albumin-Bound Paclitaxel in Patients With Advanced Cervical Cancer Who Have Progressive Disease or Intolerable Toxicity After First-Line Standard Chemotherapy
This is a single-arm, open-label, multicentre, phase II clinical study.Subjects can only enter this study after they meet the inclusion and exclusion criteria.All enrolled patients will receive the treatment with HLX10 combined…
- Trial name
- NCT04150575
- Testing
- HLX10+Albumin-Bound Paclitaxel
- Where
- China
- Volunteers
- 21 people
- Sponsor
- Shanghai Henlius Biotech
Ovarian Cancer
A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Other Anticancer Drugs in Adult Participants With Ovarian Cancer
Ovarian cancer (OC) is a lethal disease. The purpose of this study is to assess the safety, pharmacokinetics and efficacy of ABBV901, alone or in combination with other anticancer drugs, in participants with ovarian cancer.
- Trial name
- NCT07278336
- Testing
- ABBV-901, Bevacizumab, Carboplatin
- Where
- 27 sites in United States, Australia and 6 more
- Volunteers
- 285 people
- Sponsor
- AbbVie
Kidney Disease, Chronic Kidney Disease
Study to Assess Darbepoetin Alfa in Subjects With Chronic Kidney Disease
The purpose of this study is to determine whether darbepoetin alfa manufactured by the current "roller bottle" technology and darbepoetin alfa manufactured by a serum free process have a comparable safety profile.
- Trial name
- NCT00093977
- Testing
- darbepoetin alfa SF
- Volunteers
- 1,100 people
- Sponsor
- Amgen
Healthy
A Phase 1 Single and Multiple Ascending Dose Study of LTG-001 Administered Orally in Healthy Participants
This is a sequential, randomized, double-blind, placebo-controlled Phase 1 single (SAD) and multiple (MAD) ascending dose study to evaluate the safety, tolerability, and pharmacokinetics (PK) of orally or intravenously…
- Trial name
- NCT06049095
- Testing
- LTG-001
- Where
- New Zealand
- Volunteers
- 204 people, healthy volunteers welcome
- Sponsor
- Latigo Biotherapeutics
Renal Impairment
Pharmacokinetics and Safety of BV100 Administered as Single Intravenous Infusion to Subjects With Renal Impairment
To investigate the pharmacokinetics (PK) of rifabutin in subjects with renal impairment after single intravenous (IV) infusion of BV100
- Trial name
- NCT05086107
- Testing
- BV100
- Where
- Hungary
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- BioVersys AG
Healthy
A Study in Healthy People to Test How 2 Different Formulations of BI 695501 Are Taken up by the Body When Given as an Injection
The main objective of this trial is to compare the pharmacokinetics (PK) of 40 mg BI 695501 100 mg/mL with 40 mg BI 695501 50 mg/mL following single subcutaneous administration.
- Trial name
- NCT05203289
- Testing
- BI 695501 - higher concentration, BI 695501 - lower concentration
- Where
- 2 sites in United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy
Sumatriptan Succinate 100 mg Tablets Under Fasting Conditions
The objective of this study is to compare the rate and extent of absorption of sumatriptan from a test formulation of Sumatriptan Succinate 100 mg Tablets versus the reference Imitrex® 100 mg Tablets under fasting conditions.
- Trial name
- NCT00847405
- Testing
- Sumatriptan Succinate, Imitrex®
- Where
- Canada
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Teva Pharmaceuticals USA
Chronic Kidney Disease Stage 5
Study to Assess Pegloticase (KRYSTEXXA®) in Patients on Hemodialysis
This is a Phase 1 single dose study conducted to evaluate the PK and PD of pegloticase administered to hemodialysis patients. A single dose of pegloticase will be administered intravenously to male or female hemodialysis patients…
- Trial name
- NCT01739660
- Testing
- Pegloticase
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Savient Pharmaceuticals
HPV-Related Squamous Cell Carcinoma, HPV-Related Cervical Squamous Cell Carcinoma
Phase 1/2 Study of Autologous SCG142 TCR T Cells in Patients With HPV16/52-positive Carcinoma
This is a phase 1/2, open-label, single arm, multicenter study in patients with advanced or metastatic HPV16- or HPV52-positive carcinomas who have progressed after at least one line of systemic therapy, including but not limited…
- Conditions
- HPV-Related Squamous Cell Carcinoma, HPV-Related Cervical Squamous Cell Carcinoma, HPV-Related Vulvar Squamous Cell Carcinoma, HPV-Related Penile Squamous Cell Carcinoma
- Trial name
- NCT06505551
- Testing
- SCG142, Cyclophosphamide, Fludarabine
- Volunteers
- 66 people
- Sponsor
- SCG Cell Therapy Pte. Ltd.
Safety Issues, Tolerance
First-in-human Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of C106 in Healthy Subjects
This is a FIH, double-blind, placebo-controlled, within-group randomised, trial designed to evaluate the safety, tolerability, and pharmacokinetics (PK) of single and multiple ascending oral doses of compound 106 (C106) in…
- Conditions
- Safety Issues, Tolerance, Idiopathic Pulmonary Fibrosis, Pulmonary Hypertension
- Trial name
- NCT05427253
- Testing
- C106 solution
- Where
- Sweden
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Vicore Pharma AB
Healthy Subjects
A Study to Compare the Macitentan-tadalafil Fixed Dose Combination Tablet Relative to the Concomitant Administration of the Reference Tablets of Macitentan and Tadalafil in Healthy Subjects
The primary objective of this study is to demonstrate that macitentan and tadalafil administered as a fixed combination is bioequivalent to both compounds given as separate tablets given at the same doses as in the fixed…
- Trial name
- NCT03215966
- Testing
- Macitentan / tadalafil FDC, Macitentan (Opsumit®), Tadalafil (Adcirca®)
- Where
- Germany
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Actelion
Urinary Bladder Diseases, Urinary Bladder Overactive
A Trial Comparing Combination Treatment (Solifenacin Plus Mirabegron) With One Treatment Alone (Solifenacin)
The purpose of this study was to see if adding a new type of medication recently approved to treat overactive bladder (mirabegron) to an antimuscarinic treatment (solifenacin) would be more effective in controlling incontinence…
- Conditions
- Urinary Bladder Diseases, Urinary Bladder Overactive, Urologic Diseases
- Trial name
- BESIDE (NCT01908829)
- Testing
- mirabegron 25 mg, mirabegron 50 mg, solifenacin 5 mg
- Where
- 219 sites in United States, Armenia and 29 more
- Volunteers
- 2,174 people
- Sponsor
- Astellas Pharma Europe Ltd.
Pharmacokinetics, Pharmacodynamics
A Study to Evaluate the Safety and Tolerability of YM150 in Healthy Caucasian and Japanese Male and Female Subjects, and to Assess the Effect That Gender May Have on Its Actions in the Body
The study aims to investigate the effect of YM150 and to compare gender and ethnic differences in healthy Caucasian and Japanese male and female subjects.
- Conditions
- Pharmacokinetics, Pharmacodynamics, Healthy Subjects, Caucasian
- Trial name
- NCT01655056
- Testing
- YM150
- Where
- Germany
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Europe B.V.
Healthy
A Food Effect Study With ZN-c5 in Healthy Post-Menopausal Subjects
This is a single-center, randomized, open-label, two-period, 2-way crossover food effect study to determine the comparative bioavailability of ZN-c5 under fed and fasting conditions, following single-dose administration of ZN-c5…
- Trial name
- NCT04561752
- Testing
- ZN-c5
- Where
- New Zealand
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Zeno Alpha Inc.
QTc Evaluation, Electrocardiography
Influence of Moxifloxacin on QTc Interval in Healthy Subjects for Positive Control Validation
The aim of this study is to investigate the effect of moxifloxacin on the QT interval in order to gain information on the validity of results that will be collected during another clinical study testing riociguat in patients with…
- Trial name
- NCT01014247
- Testing
- Avelox (Moxifloxacin, BAY12-8039)
- Where
- 6 sites in Australia, Germany and 2 more
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Bayer
Chagas Disease
Study to Assess the Food Effect on the Pharmacokinetics of Nifurtimox Tablets in Chronic Chagas' Patients
This study will evaluate the effect of food on the absorption of the drug as well as safety and tolerability of the novel 30 mg tablet (administered as 120 mg dose) in adults suffering from chronic Chagas' disease when…
- Trial name
- NCT02606864
- Testing
- Nifurtimox (BAYa2502)
- Where
- Argentina
- Volunteers
- 36 people
- Sponsor
- Bayer
Healthy Subjects, Pharmacokinetics of ASP8232
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of ASP8232 in Subjects With Renal Impairment and in Type 2 Diabetes Mellitus Subjects With Chronic Kidney Disease
This study consists of two parts. Part 1 evaluates the effect of renal impairment on the PK and PD of a single dose of ASP8232. In addition, the safety and tolerability will be assessed.
- Conditions
- Healthy Subjects, Pharmacokinetics of ASP8232, Pharmacodynamics of ASP8232, Chronic Kidney Disease (CKD)
- Trial name
- NCT02218099
- Testing
- ASP8232
- Where
- 3 sites in Bulgaria, Moldova and 1 more
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Europe B.V.
Healthy
A Study in Healthy People to Test How 2 Different Formulations of a Combination Treatment (Vicadrostat and Empagliflozin) Are Taken up in the Body and How Food Influences the Amount of the Medicines in the Blood
To investigate the relative bioavailability of two different vicadrostat/empagliflozin combinations. Additionally, the trial investigates the effect of food on the pharmacokinetics of the vicadrostat/empagliflozin.
- Trial name
- NCT07133399
- Testing
- vicadrostat / empagliflozin combination 1, vicadrostat / empagliflozin 2
- Where
- Germany
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
End Stage Renal Disease
Clinical Evaluation of a Vascular Venous Anastomotic Connector [InterGraft VIG-only Study]
The InterGraft™ Venous Anastomotic Connector provides an endovascular, minimally invasive means for attachment of an arteriovenous graft to a vein in the upper extremity.
- Trial name
- NCT02532621
- Testing
- Venous InterGraft Connector, sutured arterial anastomosis of an implanted vascular graft for hemodialysis, hemodialysis
- Where
- 10 sites in United States
- Volunteers
- 158 people
- Sponsor
- Phraxis, Inc.
Pulmonary Disease, Chronic Obstructive
Study to Assess the Safety and PK of GSK573719 and GSK573719/GW642444(VI) Combination in Healthy Subjects and Subjects With Severe Renal Impairment
This study will assess the safety and pharmacokinetics of inhaled GSK573719 and GSK573719/vilanterol combination in healthy subjects and in subjects with severe renal impairment.
- Trial name
- NCT01571999
- Testing
- Inhaled GSK573719, Inhaled GSK573719/vilanterol
- Where
- 2 sites in Czechia, Hungary
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.